Premium
Pharmacological effects of HR 375: A new potential antipsychotic agent
Author(s) -
Hock Franz J.,
Kruse Hansjörg,
Gerhards Hermann J.,
Konz Elmar
Publication year - 1985
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430060403
Subject(s) - apomorphine , catalepsy , stereotypy , amphetamine , pharmacology , antipsychotic agent , sedative , antipsychotic drug , antipsychotic , chemistry , dopamine , anesthesia , psychology , medicine , haloperidol , dopaminergic , schizophrenia (object oriented programming) , psychiatry
HR 375, a 3‐(4‐(3‐(4‐fluorobenzoyl)‐propyl‐piperazino‐l‐yl‐isoquinolino‐ hydrochloride is a new compound with marked effects in tests of predictive value for neuroleptic activity. Its pharmacological profile is different from classical neuroleptics. HR 375 has inhibitory activity in apomorphine‐induced climbing, amphetamine aggregation toxicity, Sidman avoidance, and amphetamine‐induced hypermotility. On the other hand, only weak activity is seen in antagonizing amphetamine‐induced stereotypy, apomorphine‐turning, and apomorphine emesis. It does not include catalepsy in rats and cynomolgus monkeys even in high doses. Also, its sedative or muscle relaxant properties are weak and short‐lasting. The psychopharmacological profile of HR 375 indicates a split between its effects on the mesolimbic and nigrostriatal system.